vs
金宝汤（CPB）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是金宝汤的1.8倍（$4.7B vs $2.7B），梯瓦制药净利率更高（10.2% vs 7.2%，领先3.0%），梯瓦制药同比增速更快（11.4% vs -3.4%），梯瓦制药自由现金流更多（$1.0B vs $97.0M），过去两年梯瓦制药的营收复合增速更高（11.1% vs 4.4%）
金宝汤是美国知名食品企业，核心旗舰产品为罐装汤品。其品牌旗下众多产品采用的经典红白罐设计已成为美国文化符号之一，艺术家安迪·沃霍尔创作的金宝汤罐系列波普艺术作品更让这一设计广为人知。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
CPB vs TEVA — 直观对比
营收规模更大
TEVA
是对方的1.8倍
$2.7B
营收增速更快
TEVA
高出14.8%
-3.4%
净利率更高
TEVA
高出3.0%
7.2%
自由现金流更多
TEVA
多$919.0M
$97.0M
两年增速更快
TEVA
近两年复合增速
4.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.7B | $4.7B |
| 净利润 | $194.0M | $481.0M |
| 毛利率 | 29.6% | 56.4% |
| 营业利润率 | 12.6% | 6.4% |
| 净利率 | 7.2% | 10.2% |
| 营收同比 | -3.4% | 11.4% |
| 净利润同比 | -11.0% | 321.7% |
| 每股收益（稀释后） | $0.65 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPBTEVA
| Q4 25 | $2.7B | $4.7B | ||
| Q3 25 | $2.3B | $4.5B | ||
| Q2 25 | $2.5B | $4.2B | ||
| Q1 25 | $2.7B | $3.9B | ||
| Q4 24 | $2.8B | $4.2B | ||
| Q3 24 | $2.3B | $4.3B | ||
| Q2 24 | $2.4B | $4.2B | ||
| Q1 24 | $2.5B | $3.8B |
净利润CPBTEVA
| Q4 25 | $194.0M | $481.0M | ||
| Q3 25 | $145.0M | $433.0M | ||
| Q2 25 | $66.0M | $282.0M | ||
| Q1 25 | $173.0M | $214.0M | ||
| Q4 24 | $218.0M | $-217.0M | ||
| Q3 24 | $-3.0M | $-437.0M | ||
| Q2 24 | $133.0M | $-846.0M | ||
| Q1 24 | $203.0M | $-139.0M |
毛利率CPBTEVA
| Q4 25 | 29.6% | 56.4% | ||
| Q3 25 | 30.4% | 51.4% | ||
| Q2 25 | 29.4% | 50.3% | ||
| Q1 25 | 30.5% | 48.2% | ||
| Q4 24 | 31.3% | 50.2% | ||
| Q3 24 | 29.4% | 49.6% | ||
| Q2 24 | 30.9% | 48.6% | ||
| Q1 24 | 31.6% | 46.4% |
营业利润率CPBTEVA
| Q4 25 | 12.6% | 6.4% | ||
| Q3 25 | 11.6% | 19.7% | ||
| Q2 25 | 6.5% | 10.9% | ||
| Q1 25 | 12.2% | 13.3% | ||
| Q4 24 | 13.2% | -0.7% | ||
| Q3 24 | 3.4% | -1.2% | ||
| Q2 24 | 10.5% | -0.1% | ||
| Q1 24 | 12.9% | -5.7% |
净利率CPBTEVA
| Q4 25 | 7.2% | 10.2% | ||
| Q3 25 | 6.2% | 9.7% | ||
| Q2 25 | 2.7% | 6.8% | ||
| Q1 25 | 6.4% | 5.5% | ||
| Q4 24 | 7.9% | -5.1% | ||
| Q3 24 | -0.1% | -10.1% | ||
| Q2 24 | 5.6% | -20.3% | ||
| Q1 24 | 8.3% | -3.6% |
每股收益（稀释后）CPBTEVA
| Q4 25 | $0.65 | $0.42 | ||
| Q3 25 | $0.49 | $0.37 | ||
| Q2 25 | $0.22 | $0.24 | ||
| Q1 25 | $0.58 | $0.18 | ||
| Q4 24 | $0.72 | $-0.19 | ||
| Q3 24 | $-0.01 | $-0.39 | ||
| Q2 24 | $0.44 | $-0.75 | ||
| Q1 24 | $0.68 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $168.0M | $3.6B |
| 总债务越低越好 | $6.1B | — |
| 股东权益账面价值 | $4.0B | $7.9B |
| 总资产 | $15.2B | $40.7B |
| 负债/权益比越低杠杆越低 | 1.54× | — |
8季度趋势，按日历期对齐
现金及短期投资CPBTEVA
| Q4 25 | $168.0M | $3.6B | ||
| Q3 25 | $132.0M | $2.2B | ||
| Q2 25 | $143.0M | $2.2B | ||
| Q1 25 | $829.0M | $1.7B | ||
| Q4 24 | $808.0M | $3.3B | ||
| Q3 24 | $108.0M | $3.3B | ||
| Q2 24 | $107.0M | $2.3B | ||
| Q1 24 | $169.0M | $3.0B |
总债务CPBTEVA
| Q4 25 | $6.1B | — | ||
| Q3 25 | $6.1B | — | ||
| Q2 25 | $6.1B | — | ||
| Q1 25 | $6.5B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $5.8B | — | ||
| Q2 24 | $5.8B | — | ||
| Q1 24 | $4.5B | — |
股东权益CPBTEVA
| Q4 25 | $4.0B | $7.9B | ||
| Q3 25 | $3.9B | $7.3B | ||
| Q2 25 | $3.9B | $6.8B | ||
| Q1 25 | $3.9B | $6.3B | ||
| Q4 24 | $3.8B | $5.4B | ||
| Q3 24 | $3.8B | $6.1B | ||
| Q2 24 | $3.9B | $6.4B | ||
| Q1 24 | $3.8B | $7.3B |
总资产CPBTEVA
| Q4 25 | $15.2B | $40.7B | ||
| Q3 25 | $14.9B | $39.9B | ||
| Q2 25 | $14.8B | $40.1B | ||
| Q1 25 | $15.9B | $38.4B | ||
| Q4 24 | $16.1B | $39.3B | ||
| Q3 24 | $15.2B | $41.8B | ||
| Q2 24 | $15.2B | $41.3B | ||
| Q1 24 | $12.1B | $42.8B |
负债/权益比CPBTEVA
| Q4 25 | 1.54× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | 1.75× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.47× | — | ||
| Q1 24 | 1.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $224.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $97.0M | $1.0B |
| 自由现金流率自由现金流/营收 | 3.6% | 21.6% |
| 资本支出强度资本支出/营收 | 4.7% | 3.0% |
| 现金转化率经营现金流/净利润 | 1.15× | 2.41× |
| 过去12个月自由现金流最近4个季度 | $687.0M | $1.1B |
8季度趋势，按日历期对齐
经营现金流CPBTEVA
| Q4 25 | $224.0M | $1.2B | ||
| Q3 25 | $259.0M | $369.0M | ||
| Q2 25 | $135.0M | $227.0M | ||
| Q1 25 | $512.0M | $-105.0M | ||
| Q4 24 | $225.0M | $575.0M | ||
| Q3 24 | $288.0M | $693.0M | ||
| Q2 24 | $213.0M | $103.0M | ||
| Q1 24 | $510.0M | $-124.0M |
自由现金流CPBTEVA
| Q4 25 | $97.0M | $1.0B | ||
| Q3 25 | $129.0M | $233.0M | ||
| Q2 25 | $50.0M | $131.0M | ||
| Q1 25 | $411.0M | $-232.0M | ||
| Q4 24 | $115.0M | $446.0M | ||
| Q3 24 | $147.0M | $545.0M | ||
| Q2 24 | $100.0M | $6.0M | ||
| Q1 24 | $390.0M | $-248.0M |
自由现金流率CPBTEVA
| Q4 25 | 3.6% | 21.6% | ||
| Q3 25 | 5.6% | 5.2% | ||
| Q2 25 | 2.0% | 3.1% | ||
| Q1 25 | 15.3% | -6.0% | ||
| Q4 24 | 4.1% | 10.5% | ||
| Q3 24 | 6.4% | 12.6% | ||
| Q2 24 | 4.2% | 0.1% | ||
| Q1 24 | 15.9% | -6.5% |
资本支出强度CPBTEVA
| Q4 25 | 4.7% | 3.0% | ||
| Q3 25 | 5.6% | 3.0% | ||
| Q2 25 | 3.4% | 2.3% | ||
| Q1 25 | 3.8% | 3.3% | ||
| Q4 24 | 4.0% | 3.1% | ||
| Q3 24 | 6.1% | 3.4% | ||
| Q2 24 | 4.8% | 2.3% | ||
| Q1 24 | 4.9% | 3.2% |
现金转化率CPBTEVA
| Q4 25 | 1.15× | 2.41× | ||
| Q3 25 | 1.79× | 0.85× | ||
| Q2 25 | 2.05× | 0.80× | ||
| Q1 25 | 2.96× | -0.49× | ||
| Q4 24 | 1.03× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 2.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPB
| Baked Snacks | $995.0M | 37% |
| Snacks | $914.0M | 34% |
| Simple Meals | $580.0M | 22% |
| Beverages | $168.0M | 6% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
